Preclinical evaluation of [¹⁸F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson's disease: pharmacokinetic and efficacy analysis.

ABSTRACT:

Background

N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT), the representative cocaine derivative used in dopamine transporter imaging, is a promising biomarker, as it reflects the severity of Parkinson's disease (PD). ¹²³I- and ¹⁸F-labeled FP-CIT has been used for PD diagnosis. However, preclinical studies evaluating [¹⁸F]FP-CIT as a potential diagnostic biomarker are scarce. Among translational research advancements from bench to bedside, translating preclinical findings into clinical practice is one-directional. The aim of this study is to employ a circular approach, beginning back from the preclinical stage, progressing to the supplementation of [¹⁸F]FP-CIT, and subsequently returning to clinical application

SUBMITTER: Ahn JH 

PROVIDER: S-EPMC11222350 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature